Zurich and Allianz reveal Covid-19 hits
May 15 2020 by Andrew Tjaardstra
-
IAG on track to deliver FY 2025 guidance: CEO
- October 24
The Australian carrier has guided an insurance margin of 13.5-15.5%, and GWP growth of ‘mid-to-high single digit' in the current financial year.
-
Hong Kong’s Nova Insurance FY 2024 revenue up 3.6% to US$14.7m
- September 16
The broker reported robust retention ratios and added new accounts, including a public utility, listed companies and educational institutions, according to a stock exchange filing by its parent FSE Lifestyle.
-
Japanese P&C carriers 2023 underwriting profit rises 55% to US$1.2bn
- September 6
Net premium income rose to US$63.3bn as net claims paid dropped by US$370m during the financial year, according to Toa Re's 2024 annual report citing results of 29 members of the General Insurance Association of Japan.
-
Lloyd’s logs best interim results since 2007 as H1 underwriting profit up 24%
- September 5
The market’s COR improved to 83.7% from 85.2% a year ago, as its underwriting profit rose to US$4.07bn, thanks to premium growth and better investment returns.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
